Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Investigators won’t pull back the covers from the latest mid-stage data on fitusiran for a few days yet, but Alnylam $ALNY and its Big Pharma partners at Sanofi Genzyme $SNY have fired the starter pistol on an ambitious Phase III program for the antithrombin hemophilia drug that will look to field a rival to Roche’s closely watched emicizumab (ACE910).
The companies outlined their plans for the three studies in the pivotal effort, which will collectively require 250 patients with top-line data due in mid- to late-2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.